- Title
- Use of individualized starting dose and niraparib hematologic adverse event management costs in ovarian cancer
- Creators
- Whitney Graybill - University of South CarolinaIgnace Vergote - University Hospitals Leuven, Leuven Cancer Institute, Leuven, BelgiumBhavana Pothuri - New York University Langone Health, New York, NY, United StatesMaarit Anttila - Kuopio University HospitalDavid O'Malley - The Ohio State UniversityDomenica Lorusso - Università Cattolica del Sacro CuoreAshley Haggerty - Hackensack Meridian HealthMichel Fabbro - Institut Regional du Cancer de MontpellierJohn Chan - California Pacific Medical Center, Palo Alto and Sutter Cancer Research Consortium, San Francisco, CA, United StatesFlorian Heitz - Kliniken Essen-MitteLyndsay Willmott - PhoenixIlan Bruchim - Hillel Yaffe Medical CenterYing Zhuo - Kadlec Hematology and Oncology Clinic, Richland, WA, United StatesPurificación Estévez-García - Hospital Universitario Virgen del RocíoBradley Monk - University of ArizonaHannelore Denys - Ghent University HospitalAnja Knudsen - Odense University HospitalAnna Tinker - University of British ColumbiaLuis Manso Sánchez - Hospital Universitario 12 De OctubreDiane Provencher - Université de MontréalM. Pilar Barretina-Ginesta - Instituto Catalán de Oncología, Girona, SpainJohn Hartman - GSK, Philadelphia, PA, United StatesDonna Booth - GSK, Durham, NC, United StatesAntonio González-Martín - Universidad de Navarra
- Publication Details
- Gynecologic oncology, Vol.190, pp.S274-S275
- Publisher
- Elsevier Inc
- Identifiers
- 991006118537202656
- Academic Unit
- Obstetrics & Gynecology
- Language
- English
- Resource Type
- Journal article
Journal article
Use of individualized starting dose and niraparib hematologic adverse event management costs in ovarian cancer
Gynecologic oncology, Vol.190, pp.S274-S275
11/2024
Metrics
1 Record Views